- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03939481
Behandlingseffekter på utvikling av kjemoterapi-indusert perifer nevropati hos pasienter med kreft
En prospektiv observasjonskohortstudie for å utvikle en prediktiv modell for taksanindusert perifer nevropati hos kreftpasienter
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.
Studieoversikt
Status
Forhold
- Anatomisk stadium I brystkreft AJCC v8
- Anatomisk stadium IA brystkreft AJCC v8
- Anatomisk stadium IB brystkreft AJCC v8
- Anatomisk stadium II brystkreft AJCC v8
- Anatomisk stadium IIA brystkreft AJCC v8
- Anatomisk stadium IIB brystkreft AJCC v8
- Anatomisk stadium III brystkreft AJCC v8
- Anatomisk stadium IIIA brystkreft AJCC v8
- Anatomisk stadium IIIB brystkreft AJCC v8
- Anatomisk stadium IIIC brystkreft AJCC v8
- Prognostisk stadium I brystkreft AJCC v8
- Prognostisk stadium IA brystkreft AJCC v8
- Prognostisk stadium IB brystkreft AJCC v8
- Prognostisk stadium II brystkreft AJCC v8
- Prognostisk stadium IIA brystkreft AJCC v8
- Prognostisk stadium IIB brystkreft AJCC v8
- Prognostisk stadium III brystkreft AJCC v8
- Prognostisk stadium IIIA brystkreft AJCC v8
- Prognostisk stadium IIIB brystkreft AJCC v8
- Prognostisk stadium IIIC brystkreft AJCC v8
- Ikke-småcellet lungekarsinom
- Stadium III lungekreft AJCC v8
- Trinn II lungekreft AJCC v8
- Stage IIA lungekreft AJCC v8
- Stadium IIB lungekreft AJCC v8
- Stadium IIIA lungekreft AJCC v8
- Stadium IIIB lungekreft AJCC v8
- Stage I lungekreft AJCC v8
- Stadium IA1 lungekreft AJCC v8
- Trinn IA2 lungekreft AJCC v8
- Stadium IA3 lungekreft AJCC v8
- Stage IB lungekreft AJCC v8
- Stadium IIIC lungekreft AJCC v8
- Stadium III Eggstokkreft AJCC v8
- Stadium IIIA Eggstokkreft AJCC v8
- Stadium IIIA1 Eggstokkreft AJCC v8
- Stadium IIIA2 Eggstokkreft AJCC v8
- Stadium IIIB Eggstokkreft AJCC v8
- Stadium IIIC Eggstokkreft AJCC v8
- Stadium II Eggstokkreft AJCC v8
- Stage IIA Eggstokkreft AJCC v8
- Stadium IIB Eggstokkreft AJCC v8
- Fase I Eggstokkreft AJCC v8
- Stadium IA Eggstokkreft AJCC v8
- Stadium IB Eggstokkreft AJCC v8
- Stage IC Eggstokkreft AJCC v8
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To develop and validate a clinical risk prediction model using clinical factors for the development of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.
SECONDARY OBJECTIVES:
I. To examine patient-reported outcomes (PROs) and objective measures of chemotherapy induced peripheral neuropathy (CIPN) to better define the phenotype of peripheral neuropathy in this patient population.
II. To assess the incidence of CIPN within one year in this patient population. III. To identify predictors of treatment dose reductions, delays, and discontinuations associated with CIPN symptoms in this patient population.
OTHER OBJECTIVES:
I. To collect serum and plasma samples for future testing for biomarker and mechanistic studies of CIPN.
OUTLINE:
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Independencia, Chile, 8380455
- Instituto Nacional del Cancer
-
-
-
-
-
Bogotá, Colombia, 99999
- Instituto Nacional De Cancerologia
-
-
-
-
California
-
Antioch, California, Forente stater, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Dublin, California, Forente stater, 94568
- Kaiser Permanente Dublin
-
Fremont, California, Forente stater, 94538
- Kaiser Permanente-Fremont
-
Fresno, California, Forente stater, 93720
- Kaiser Permanente-Fresno
-
Oakland, California, Forente stater, 94611
- Kaiser Permanente-Oakland
-
Palm Springs, California, Forente stater, 92262
- Desert Regional Medical Center
-
San Francisco, California, Forente stater, 94115
- Kaiser Permanente-San Francisco
-
San Jose, California, Forente stater, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Forente stater, 94577
- Kaiser Permanente San Leandro
-
San Rafael, California, Forente stater, 94903
- Kaiser San Rafael-Gallinas
-
Santa Clara, California, Forente stater, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, Forente stater, 95403
- Kaiser Permanente-Santa Rosa
-
Vacaville, California, Forente stater, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Forente stater, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Forente stater, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rocky Mountain Regional VA Medical Center
-
-
Delaware
-
Dover, Delaware, Forente stater, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, Forente stater, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Fort Myers, Florida, Forente stater, 33905
- Florida Gynecologic Oncology
-
Pensacola, Florida, Forente stater, 32504
- Sacred Heart Hospital
-
-
Georgia
-
Savannah, Georgia, Forente stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Forente stater, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Forente stater, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Forente stater, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Forente stater, 96819
- Kaiser Permanente Moanalua Medical Center
-
Lihue, Hawaii, Forente stater, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Forente stater, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Forente stater, 96701
- Hawaii Cancer Care - Savio
-
-
Illinois
-
Centralia, Illinois, Forente stater, 62801
- Centralia Oncology Clinic
-
Danville, Illinois, Forente stater, 61832
- Carle on Vermilion
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forente stater, 62401
- Carle Physician Group-Effingham
-
Evergreen Park, Illinois, Forente stater, 60805
- Little Company of Mary Hospital
-
Hines, Illinois, Forente stater, 60141
- Edward Hines Jr VA Hospital
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Moline, Illinois, Forente stater, 61265
- Trinity Medical Center
-
O'Fallon, Illinois, Forente stater, 62269
- Cancer Care Center of O'Fallon
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Urbana, Illinois, Forente stater, 61801
- The Carle Foundation Hospital
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic PC - Ames
-
Cedar Rapids, Iowa, Forente stater, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Forente stater, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, Forente stater, 52402
- Physicians' Clinic of Iowa PC
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- Medical Oncology and Hematology Associates-West Des Moines
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Medical Oncology and Hematology Associates-Laurel
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays, Kansas, Forente stater, 67601
- HaysMed University of Kansas Health System
-
Lawrence, Kansas, Forente stater, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Forente stater, 66061
- Olathe Health Cancer Center
-
Salina, Kansas, Forente stater, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Forente stater, 66606
- University of Kansas Health System Saint Francis Campus
-
Wichita, Kansas, Forente stater, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Forente stater, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Forente stater, 67208
- Associates In Womens Health
-
-
Kentucky
-
Bardstown, Kentucky, Forente stater, 40004
- Flaget Memorial Hospital
-
Lexington, Kentucky, Forente stater, 40509
- Saint Joseph Hospital East
-
London, Kentucky, Forente stater, 40741
- Saint Joseph London
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70112
- Tulane University Health Sciences Center
-
New Orleans, Louisiana, Forente stater, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, Forente stater, 70112
- Louisiana State University Health Science Center
-
Shreveport, Louisiana, Forente stater, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, Forente stater, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Forente stater, 04915
- Waldo County General Hospital
-
Biddeford, Maine, Forente stater, 04005
- MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
-
Rockport, Maine, Forente stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forente stater, 04073
- MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
-
Scarborough, Maine, Forente stater, 04074
- Maine Medical Center- Scarborough Campus
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21204
- Greater Baltimore Medical Center
-
Easton, Maryland, Forente stater, 21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Burlington, Massachusetts, Forente stater, 01805
- Lahey Hospital and Medical Center
-
Winchester, Massachusetts, Forente stater, 01890
- Winchester Hospital
-
-
Michigan
-
Grand Rapids, Michigan, Forente stater, 49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids, Michigan, Forente stater, 49503
- Mercy Health Saint Mary's
-
Reed City, Michigan, Forente stater, 49677
- Spectrum Health Reed City Hospital
-
Traverse City, Michigan, Forente stater, 49684
- Munson Medical Center
-
Wyoming, Michigan, Forente stater, 49519
- Metro Health Hospital
-
-
Minnesota
-
Burnsville, Minnesota, Forente stater, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Forente stater, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy Hospital
-
Deer River, Minnesota, Forente stater, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Forente stater, 55805
- Essentia Health Cancer Center
-
Edina, Minnesota, Forente stater, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Forente stater, 55432
- Unity Hospital
-
Hibbing, Minnesota, Forente stater, 55746
- Essentia Health Hibbing Clinic
-
Maple Grove, Minnesota, Forente stater, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Forente stater, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Forente stater, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forente stater, 55407
- Abbott-Northwestern Hospital
-
Monticello, Minnesota, Forente stater, 55362
- Monticello Cancer Center
-
Robbinsdale, Minnesota, Forente stater, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Forente stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Sandstone, Minnesota, Forente stater, 55072
- Essentia Health Sandstone
-
Stillwater, Minnesota, Forente stater, 55082
- Lakeview Hospital
-
Virginia, Minnesota, Forente stater, 55792
- Essentia Health Virginia Clinic
-
Willmar, Minnesota, Forente stater, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Forente stater, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Forente stater, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Rolla, Missouri, Forente stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- CHI Health Saint Francis
-
-
New Hampshire
-
Nashua, New Hampshire, Forente stater, 03060
- Saint Joseph Hospital
-
-
New York
-
New York, New York, Forente stater, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
North Carolina
-
Asheboro, North Carolina, Forente stater, 27203
- Randolph Hospital
-
Asheville, North Carolina, Forente stater, 28803
- AdventHealth Infusion Center Asheville
-
Burlington, North Carolina, Forente stater, 27215
- Cone Health Cancer Center at Alamance Regional
-
Clinton, North Carolina, Forente stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Clyde, North Carolina, Forente stater, 28721
- AdventHealth Infusion Center Haywood
-
Gastonia, North Carolina, Forente stater, 28054
- CaroMont Regional Medical Center
-
Goldsboro, North Carolina, Forente stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Greensboro, North Carolina, Forente stater, 27403
- Cone Health Cancer Center
-
Hendersonville, North Carolina, Forente stater, 28792
- AdventHealth Hendersonville
-
Jacksonville, North Carolina, Forente stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
New Bern, North Carolina, Forente stater, 28561
- CarolinaEast Medical Center
-
Pinehurst, North Carolina, Forente stater, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Rocky Mount, North Carolina, Forente stater, 27804
- Nash General Hospital
-
Supply, North Carolina, Forente stater, 28462
- NHRMC Radiation Oncology - Supply
-
Wilmington, North Carolina, Forente stater, 28401
- New Hanover Regional Medical Center/Zimmer Cancer Center
-
-
North Dakota
-
Minot, North Dakota, Forente stater, 58701
- Trinity Cancer Care Center
-
-
Ohio
-
Akron, Ohio, Forente stater, 44307
- Cleveland Clinic Akron General
-
Cincinnati, Ohio, Forente stater, 45220
- Good Samaritan Hospital - Cincinnati
-
-
Oregon
-
Portland, Oregon, Forente stater, 97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Phoenixville, Pennsylvania, Forente stater, 19460
- Phoenixville Hospital
-
-
Rhode Island
-
Warwick, Rhode Island, Forente stater, 02886
- Kent Hospital
-
-
South Carolina
-
Anderson, South Carolina, Forente stater, 29621
- AnMed Health Cancer Center
-
Bluffton, South Carolina, Forente stater, 29910
- Saint Joseph's/Candler - Bluffton Campus
-
Boiling Springs, South Carolina, Forente stater, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Florence, South Carolina, Forente stater, 29506
- McLeod Regional Medical Center
-
Gaffney, South Carolina, Forente stater, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forente stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forente stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Forente stater, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Forente stater, 29650
- Prisma Health Cancer Institute - Greer
-
Greer, South Carolina, Forente stater, 29651
- Gibbs Cancer Center-Pelham
-
Hilton Head Island, South Carolina, Forente stater, 29926-3827
- South Carolina Cancer Specialists PC
-
Seneca, South Carolina, Forente stater, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Forente stater, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Forente stater, 29379
- MGC Hematology Oncology-Union
-
-
Tennessee
-
Cookeville, Tennessee, Forente stater, 38501
- Cookeville Regional Medical Center
-
Kingsport, Tennessee, Forente stater, 37660
- Ballad Health Cancer Care - Kingsport
-
-
Texas
-
Lubbock, Texas, Forente stater, 79415
- UMC Cancer Center / UMC Health System
-
Lubbock, Texas, Forente stater, 79430
- Texas Tech University Health Sciences Center-Lubbock
-
-
Virginia
-
Bristol, Virginia, Forente stater, 24201
- Wellmont Medical Associates-Bristol
-
Charlottesville, Virginia, Forente stater, 22908
- University of Virginia Cancer Center
-
Mechanicsville, Virginia, Forente stater, 23116
- Bon Secours Memorial Regional Medical Center
-
Midlothian, Virginia, Forente stater, 23114
- Bon Secours Saint Francis Medical Center
-
Richmond, Virginia, Forente stater, 23226
- Bon Secours Saint Mary's Hospital
-
-
Washington
-
Issaquah, Washington, Forente stater, 98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend, Washington, Forente stater, 98368
- Jefferson Healthcare
-
-
Wisconsin
-
Ashland, Wisconsin, Forente stater, 54806
- Duluth Clinic Ashland
-
New Richmond, Wisconsin, Forente stater, 54017
- Cancer Center of Western Wisconsin
-
-
-
-
Tlalpan
-
Mexico City, Tlalpan, Mexico, 14080
- Instituto Nacional De Cancerologia de Mexico
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Participants with stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer
Beskrivelse
Inclusion Criteria:
-
Patients must have stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer based on clinical or pathologic evaluation. Patients with Stage IV disease are not eligible.
-
Patients must be planning to start treatment with a taxane-based chemotherapy as part of one of the study-approved taxane regimens (docetaxel chemotherapy regimens for treatment of breast or ovarian cancer, or paclitaxel chemotherapy regimen for treatment of breast, non-small cell lung, or ovarian cancer) within 14 days after registration. (Note that docetaxel or paclitaxel may be administered with a non-neurotoxic chemotherapy, such as cyclophosphamide, and/or biologic agent, such as trastuzumab, and/or carboplatin. Additionally, nab-paclitaxel may not be substituted for paclitaxel for purposes of this study.)
-
Patients who will receive treatment in the setting of any other clinical trial are eligible as long as it is one of the study-approved regimens. Patients may receive additional treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial in addition to any regimen approved in this study.
-
Patients must not have received a taxane (paclitaxel, docetaxel, or protein-bound paclitaxel), platinum (cisplatin, carboplatin, or oxaliplatin), vinca alkaloid (vinblastine, vincristine, or vinorelbine), or bortezomib-based chemotherapy regimen prior to registration. (Note that while patients must not have received carboplatin in the past, patients may receive a carboplatin-containing regimen after registration as part of the docetaxel or paclitaxel regimen.)
-
Patients who can complete Patient-Reported Outcome (PRO) instruments in English or Spanish must:
- Agree to complete PROs at all scheduled assessments
- Complete the baseline PRO forms prior to registration
-
Patients with pre-existing neuropathy are eligible, including those with diabetes and neurological conditions such as multiple sclerosis or Parkinson?s disease.
-
Patients must agree to submit required specimens for defined translational medicine.
-
Patients must be offered the opportunity to submit additional optional specimens for future, unspecified translational medicine and banking. With patient?s consent, specimens must be submitted.
-
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
-
As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Observational (non-study chemo, questionnaire, assessments)
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52. |
Given chemotherapy regimen
Andre navn:
Functional and sensory clinician assessments Patient and physician reported responses |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Development of Peripheral Neuropathy
Tidsramme: Up to 24 weeks
|
Will be measured as an absolute increase of >= 8 points over the baseline chemotherapy-induced peripheral neuropathy (CIPN)-20 sensory neuropathy subscale score. An absolute increase of >=8 points over baseline at any timepoint at or prior to 24 weeks (at 4, 8, 12, or 24 weeks) is considered occurrence of peripheral neuropathy. |
Up to 24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
CIPN Symptoms
Tidsramme: Up to 52 weeks
|
Patients experiencing a treatment change attributed to CIPN symptoms |
Up to 52 weeks
|
|
Dose Changes
Tidsramme: Up to 52 weeks
|
Dose reductions, delays, and discontinuations of treatment (prior to completing the original treatment plan) |
Up to 52 weeks
|
|
Health-related Quality of Life
Tidsramme: Up to 52 weeks
|
Assessed using the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29). The PROMIS-29 is a well validated assessment tool that offers both qualitative and quantitative measures of health-related quality of life. The PROMIS-29 includes 29 questions evaluating areas of physical function, anxiety, depression, fatigue, sleep, social functioning, and pain interference. The PROMIS-29 assesses severity levels of symptoms and their effect on the patient's functioning. |
Up to 52 weeks
|
|
Visual Analog Toxicity Score
Tidsramme: Up to 52 weeks
|
Assessed using the Visual Analog Toxicity Score. The Visual Analog Toxicity Score is a single question asking the physician to rate how the physician feels the patient's disease and treatment affects their daily life on a scale from 0 (no symptoms and no effect on life) to 10 (severe effects of treatment and patient would rather be dead). |
Up to 52 weeks
|
|
Patient Reported Symptom
Tidsramme: Up to 52 weeks
|
Assessed using the Patient Reported Symptom Burden Score. The Patient Reported Symptom Score at baseline contains one question to assess how cancer symptoms affect the patient's life (scale 0 [no burden at all] to 10 [a great burden]). At follow-up, the Symptom Burden Score contains five questions: 1) to assess burden of side effects of cancer treatment on life (scale 0 [no burden at all] to 10 [a great burden]), 2) to assess severity of side effects from cancer treatment (scale 0 [no side effects]) to 10 [side effects extremely severe and unbearable]), 3) to assess tolerability of side effects for set time periods (yes/no), 4) to assess level at which treatment would be considered intolerable (scale 0 [side effects not severe at all] to 10 [side effects extremely severe and unbearable]), and 5) to assess the burden of cancer symptoms and treatment symptoms (scale 0 [no burden at all] to 10 [a great burden]). |
Up to 52 weeks
|
|
Leisure-time Exercise Habits
Tidsramme: Up to 52 weeks
|
Assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ). The GSLTPAQ is a brief 4 item self-administered questionnaire of usual leisure-time exercise habits over a typical 7-day period. The Leisure Score Index (LSI) is calculated based on the first 3 questions. The LSI scores can be used to classify respondents into active (LSI > 24) and insufficiently active (LSI < 23) categories. |
Up to 52 weeks
|
|
Patient-Reported Outcomes
Tidsramme: Up to 52 weeks
|
Assessed using the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE [CTCAE Version 5.0]). PRO-CTCAE assesses 78 adverse events by self-report with 124 items. Each item uses a plain language term for the adverse event, the attribute of interest, and the standard recall period of "the past 7 days". |
Up to 52 weeks
|
|
National Cancer Institute-Common Terminology Criteria for Adverse Events
Tidsramme: Up to 52 weeks
|
The NCI-CTCAE is a subjective method to evaluate CIPN performed by a healthcare professional. The treating physician will grade the subject's dysesthesia, paresthesia, neuralgia, peripheral sensory neuropathy, and peripheral motor neuropathy on a scale of 0 to 5 depending on the severity. The advantage of the NCI-CTCAE is that the assessment is quick and easy for providers to perform, (8) but it is limited by the subjectivity of interpretation, lack of detail about location, type, and severity of impairment, and narrow scoring range. Participants will only be graded for the event types listed above, so these will only be reported as an outcome measure, and will not appear in the adverse events section of this report. |
Up to 52 weeks
|
|
Assess Incidence of CIPN
Tidsramme: Up to 52 weeks
|
Assessed using European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 (CIPN-20). The EORTC QLQ-CIPN20 is a 20-item questionnaire that evaluates CIPN using 3 subscales that assess sensory (9 items), motor (8 items), and autonomic (3 items) symptoms and functioning with each item measured on a 1-4 scale (1, not at all; 4, very much). The sensory subscale raw scores range from 1 to 36. The CIPN-20 subscale raw scores are linearly converted to a 0-100 scale such that a high score corresponds to a worse condition or more symptoms. |
Up to 52 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Meghna S Trivedi, SWOG Cancer Research Network
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i det endokrine systemet
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Sykdommer i luftveiene
- Kjønnssykdommer, kvinner
- Lungesykdommer
- Neoplasmer i endokrine kjertel
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Sykdommer i eggstokkene
- Adnexal sykdommer
- Genitale neoplasmer, kvinnelige
- Gonadal lidelser
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Neoplasmer i eggstokkene
- Karsinom, ikke-småcellet lunge
- Terapeutikk
- Medikamentell terapi
Andre studie-ID-numre
- S1714
- UG1CA189974 (U.S. NIH-stipend/kontrakt)
- S1714 (Annen identifikator: CTEP)
- NCI-2018-01568 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- SWOG-S1714 (Annen identifikator: DCP)
- S1714 (Annen identifikator: SWOG)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .